If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRevolution Beauty Regulatory News (REVB)

Share Price Information for Revolution Beauty (REVB)

Share Price is delayed by 15 minutes
Get Live Data
4.77    -0.10 (-2.05%)
Bid:
4.71
Ask:
4.76
Spread: 0.05 (1.062%)
Market Cap: £41.49m
REVB Live PriceLast checked at - London Stock Exchange

Intraday Revolution Beauty Share Chart

Result of Placing and Subscription

22 Aug 2025 08:09

RNS Number : 4225W
Revolution Beauty Group PLC
22 August 2025
Β 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN REVOLUTION BEAUTY GROUP PLC IN ANY JURISDICTION IN WHICH SUCH INVITATION, SOLICITATION, RECOMMENDATION, OFFER, SUBSCRIPTION OR ADVICE WOULD BE UNLAWFUL UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT AN OFFER OF OR SOLICITATION TO PURCHASE OR SUBSCRIBE FOR SECURITIES IN THE UNITED STATES.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THEΒ UNITED KINGDOMΒ BY VIRTUE OF THEΒ EUΒ (WITHDRAWAL) ACT 2018 ("MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN MAR) WERE TAKEN IN RESPECT OF THE PLACING WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED IN MAR), AS PERMITTED BY MAR. THIS INSIDE INFORMATION IS SET OUT IN THIS ANNOUNCEMENT. THEREFORE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION RELATING TO THE COMPANY AND ITS SECURITIES.

CAPITALISED TERMS USED IN THIS ANNOUNCEMENT (THE "ANNOUNCEMENT") HAVE THE MEANINGS GIVEN TO THEM IN THE LAUNCH ANNOUNCEMENT (AS DEFINED BELOW), UNLESS THE CONTEXT PROVIDES OTHERWISE.

22 August 2025

Revolution Beauty Group plc

("Revolution Beauty" or the "Company")

Result of Placing and Subscription

Revolution Beauty, the multi-channel mass beauty brand, is pleased to announce that, further to the announcement made earlier today (the "Launch Announcement") regarding the launch of the proposed Placing and Subscription, it has successfully raised Β£15 million (before fees and expenses), in aggregate, via the placing of 345,132,401 new ordinary shares of one penny (the "Ordinary Shares") by way of the Placing and 154,867,599 new Ordinary Shares by way of the Subscription, in each case at the Issue Price.

The Placing Shares and Subscription Shares represent 156.50% of the issued ordinary share capital of the Company prior to the Placing and Subscription.

Panmure Liberum Limited ("Panmure Liberum") is acting as nominated adviser, joint broker and joint bookrunner, alongside Zeus Capital Limited ("Zeus Capital") which is also acting as joint broker and joint bookrunner (together, the "Joint Bookrunners") in connection with the Placing and Subscription.

Retail Offer

As announced earlier today, the Company will also launch a Retail Offer through the BookBuild Platform to raise gross proceeds of up to Β£1.5 million (before fees and expenses). The Retail Offer provides existing retail Shareholders in the United Kingdom with an opportunity to participate in the Fundraise at the same issue price as the Placing and Subscription.

Related Party Transactions

As set out below, each of Iain McDonald and Neil Catto have agreed to subscribe for a total of 1,999,999 Subscription Shares pursuant to the Subscription. The relevant Directors will be treated as a "related party", and their participation in the Subscription as a "related party transaction", for the purposes of Rule 13 of the AIM Rules.

Each of Debenhams, Tom Allsworth and Adam Minto is a substantial shareholder (as defined under the AIM Rules) in the Company, and they have agreed to subscribe for a total of 298,836,934 Fundraise Shares pursuant to the Placing (in the case of Debenhams) or the Subscription (in the case of Tom Allsworth and Adam Minto). Each of Debenhams, Tom Allsworth and Adam Minto will, therefore, also be treated as a "related party", and their participation in the Fundraise as a "related party transaction", for the purposes of Rule 13 of the AIM Rules.

The independent Directors for the purposes of the Fundraise (being Colin Henry, Chris Fry and Rachel Horsefield) consider, having consulted with Panmure Liberum, the Company's nominated adviser for the purposes of the AIM Rules, that the participation in the Fundraise by (i) each of Iain McDonald and Neil Catto and (ii) Debenhams, Tom Allsworth and Adam Minto is fair and reasonable insofar as Shareholders are concerned.

The individual subscriptions for the participating Directors, and their holdings of Ordinary Shares on Admission, are set out below:

Director

Existing shareholding (Number of Ordinary Shares)

Number of new Ordinary Shares acquired

Shareholding on Admission (Number of Ordinary Shares)

% of the Enlarged Share Capital on Admission*

Iain McDonald

-

1,666,666

1,666,666

0.20

Neil Catto

-

333,333

333,333

0.04

Note: *assuming that no Retail Offer Shares are issued and that there are no changes to the Existing Share Capital between the date of this Announcement and Admission, other than the issue of the Placing Shares and the Subscription Shares

Notice of General Meeting

The Circular containing further details of the Placing, the Subscription and the Retail Offer and the Notice of General Meeting to be held the offices of Macfarlanes LLP at 20 Cursitor Street, London EC4A 1LT at 10 a.m. on 11 September 2025 is expected to be despatched to ShareholdersΒ on or around 26 August 2025 and will thereafter be available on the Company's website www.revolutionbeautyplc.com.

Admission

Application will be made to London Stock Exchange plc for the Fundraise Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and that dealings in the Fundraise Shares will commence at 8.00 a.m. on 15 September 2025, subject to the Resolutions being passed at the General Meeting.

The Fundraise Shares will, when issued, be credited as fully paid and will be issued subject to the Company's articles of association and will rank pari passu in all respects with the existing issued Ordinary Shares.

The person responsible for arranging this announcement on behalf of the Company is Neil Catto, Chief Financial Officer.

For further information:

Revolution Beauty Group Plc

Β 

Β 

Iain McDonald (Non-executive Chair) / Neil Catto (CFO)

Β 

+44 (0)20 3805 4822 (Via Headland Consultancy)

Β 

Β 

Β 

Panmure Liberum Limited (NOMAD, Joint Bookrunner, and Joint Broker)

Β 

+44 (0)20 3100 2222

Bidhi Bhoma / Dru Danford / Edward Thomas / John More

Β 

Β 

Β 

Β 

Β 

Β 

Zeus Capital (Joint Bookrunner and Joint Broker)

Β 

+44 (0)161 831 1512

Ben Robertson / Dominic King / Jordan Warburton

Β 

Β 

Β 

Β 

Headland Consultancy (Public Relations)

Β 

+44 (0)203 805 4885

Matt Denham / Antonia Pollock

Β 

Β 

IMPORTANT NOTICES

This Announcement may contain "forward-looking statements" with respect to certain of the Company's plans and its current goals and expectations relating to its future financial condition, performance, strategic initiatives, objectives and results. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "forecasts", "plans", "prepares", "anticipates", "projects", "expects", "intends", "may", "will", "seeks", "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Announcement and include statements regarding the Company's and the Directors' intentions, beliefs or current expectations concerning, amongst other things, the Company's prospects, growth and strategy. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. The Company's actual performance, achievements and financial condition may differ materially from those expressed or implied by the forward-looking statements in this Announcement. In addition, even if the Company's results of operations, performance, achievements and financial condition are consistent with the forward-looking statements in this Announcement, those results or developments may not be indicative of results or developments in subsequent periods. Any forward-looking statements that the Company makes in this Announcement speak only as of the date of such statement and (other than in accordance with their legal or regulatory obligations) neither the Company, nor the Joint Bookrunner's nor any of their respective associates, directors, officers or advisers undertakes any obligation to update such statements. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

Panmure Liberum is authorised and regulated by the Financial Conduct Authority (the "FCA") in the United Kingdom and is acting exclusively as nominated adviser, joint broker and joint bookrunner for the Company and no one else in connection with the Placing or any other matters referred to in this Announcement, and Panmure Liberum will not be responsible to anyone (including any Placees) other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Placing or any other matters referred to in this Announcement.

Zeus Capital, which is authorised and regulated in the United Kingdom by the FCA, is acting as joint broker and joint bookrunner exclusively for the Company and no one else in connection with the Placing and the contents of this Announcement and will not regard any other person (whether or not a recipient of this Announcement) as its client in relation to the Placing nor will it be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to the contents of this Announcement. Apart from the responsibilities and liabilities, if any, which may be imposed on Zeus Capital by FSMA or the regulatory regime established thereunder, Zeus Capital accepts no responsibility whatsoever, and makes no representation or warranty, express or implied, as to the contents of this Announcement including its accuracy, completeness or verification or for any other statement made or purported to be made by it, or on behalf of it, the Company or any other person, in connection with the Company and the contents of this Announcement, whether as to the past or the future. Zeus Capital accordingly disclaims all and any liability whatsoever, whether arising in tort, contract or otherwise (save as referred to above), which it might otherwise have in respect of the contents of this Announcement or any such statement.

No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by the Joint Bookrunners or by any of its affiliates or agents as to, or in relation to, the accuracy or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.

No statement in this Announcement is intended to be a profit forecast or estimate, and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

The price of shares and any income expected from them may go down as well as up and investors may not get back the full amount invested upon disposal of the shares. Past performance is no guide to future performance, and persons needing advice should consult an independent financial adviser.

The new Ordinary Shares to be issued pursuant to the Fundraise will not be admitted to trading on any stock exchange other than AIM.

Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this Announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
ROIFIFIDTTIFFIE
Date   Source Headline
8th Jun 20267:00 amRNSNew Licensing Partnership with Debenhams Group
5th Jun 20267:00 amRNSFinancial Conduct Authority Update
16th Apr 20267:00 amRNSGrant of Share Options
1st Apr 202611:35 amRNSTotal Voting Rights
11th Mar 20267:00 amRNSAppointment of Nominated Adviser
2nd Mar 202611:28 amRNSTotal Voting Rights
3rd Feb 20264:05 pmRNSTotal Voting Rights
3rd Feb 20264:05 pmRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Jan 20263:48 pmRNSTotal Voting Rights
15th Dec 20256:18 pmRNSDirector/PDMR Shareholding
1st Dec 20255:43 pmRNSTotal Voting Rights
27th Nov 20253:59 pmRNSDirector/PDMR Shareholding
27th Nov 20257:00 amRNSInterim Results
26th Nov 20256:15 pmRNSRelated Party Transaction
4th Nov 20254:32 pmRNSTotal Voting Rights
1st Oct 20257:00 amRNSTotal Voting Rights
30th Sep 20259:33 amRNSResult of AGM
24th Sep 20257:00 amRNSDirectorate Change
18th Sep 20257:00 amRNSHolding(s) in Company
17th Sep 202512:30 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSDirector/PDMR Shareholding
16th Sep 20255:17 pmRNSHolding(s) in Company
16th Sep 20259:11 amRNSHolding(s) in Company
11th Sep 20254:09 pmRNSResults of General Meeting
2nd Sep 20258:30 amRNSTotal Voting Rights
1st Sep 20255:06 pmRNSHolding(s) in Company
1st Sep 20258:33 amRNSHolding(s) in Company
29th Aug 20254:50 pmRNSFinal Results, Annual Report Posting & AGM Notice
26th Aug 20257:01 amRNSCircular Publication, Notice of GM & Board Update
26th Aug 20257:00 amRNSResult of Retail Offer to existing shareholders
22nd Aug 20254:31 pmRNSPDMR Dealing
22nd Aug 20253:30 pmRNSHolding(s) in Company
22nd Aug 20258:52 amRNSHolding(s) in Company
22nd Aug 20258:40 amRNSRetail Offer to existing shareholders
22nd Aug 20258:09 amRNSResult of Placing and Subscription
22nd Aug 20257:02 amRNSProposed Placing and Subscription via ABB
22nd Aug 20257:01 amRNSPreliminary Unaudited Results
22nd Aug 20257:00 amRNSTermination of Formal Sale Process
21st Aug 202510:51 amRNSForm 8.5 (EPT/RI)
20th Aug 202510:28 amRNSForm 8.5 (EPT/RI)
19th Aug 202512:27 pmRNSFY25 Trading Update
19th Aug 202510:01 amRNSForm 8.5 (EPT/RI)
18th Aug 202510:27 amRNSForm 8.5 (EPT/RI)
15th Aug 20254:11 pmRNSHolding(s) in Company
15th Aug 20259:57 amRNSForm 8.5 (EPT/RI)
14th Aug 202510:25 amRNSForm 8.5 (EPT/RI)
13th Aug 202510:31 amRNSForm 8.5 (EPT/RI)
12th Aug 202510:05 amRNSForm 8.5 (EPT/RI)
11th Aug 202510:26 amRNSForm 8.5 (EPT/RI)
8th Aug 202511:31 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.